Cambridge Investment Research Advisors
BCTX

Cambridge Investment Research Advisors’s Briacell Therapeutics BCTX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-75
Closed -$6K – 3515
2024
Q4 		$6K Sell
75
-34
-31% -$4.08K ﹤0.01% 3452
2024
Q3 		$20K Buy
+109
New +$12.2K ﹤0.01% 3365

Other funds holding BCTX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HWA
HHM Wealth Advisors Chattanooga, Tennessee $996M AUM 23.11% 1-Year Est. Return

Cambridge Investment Research Advisors's BCTX Position: Q1 2025 in Review

Cambridge Investment Research Advisors sold out of Briacell Therapeutics (BCTX) in Q1 2025, closing a stake of 75 shares — an estimated $6K sold.

Cambridge Investment Research Advisors first reported a position in BCTX in Q3 2024 and held it in 2 quarters. The position peaked at $20K in Q3 2024. 13 funds tracked by Wall St. Rank hold BCTX as of Q1 2025.

  • Cambridge Investment Research Advisors reported no remaining Briacell Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 75 Briacell Therapeutics shares in Q1 2025, an estimated $6K.
  • Cambridge Investment Research Advisors first reported a position in Briacell Therapeutics in Q3 2024 and held it in 2 quarters.
  • Cambridge Investment Research Advisors's Briacell Therapeutics position peaked at $20K in Q3 2024.
  • 13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2025, filed 22 Apr 2025.